International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Exploring Immunotherapeutic Approaches for Alzheimer’s Disease

Mubashir Ahmad Khan, Qurat Ul Ain Ashfaq, Danish Abbas, Bilal Atiq, Farah Saif, Muhammad Jawad Munir

Medical Student and Intern, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China; Department of Physiotherapy, Superior University, Lahore, Pakistan; Department of Pharm D, Hamdard Institute of Pharmaceutical Sciences, Islamabad, Pakistan; Department of Environmental Science and Engineering, Government College Faisalabad, Pakistan; College of Mechanical and Engineering Science Hohai University, China

Article Information

Volume / Issue6 / 2 (2025)
Pages21-27
AccessOpen Access

Publication Timeline

  • Received25 February 2025
  • Accepted19 March 2025

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder worldwide that is progressed by the accumulation of highly neurotoxic amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) of tau protein within the brain. Despite several traditional treatment methods, there is still a need to explore novel immunotherapeutic approaches for AD. We have summarized the data from the clinical side and the use of various drugs including active and passive immunotherapies. Immunotherapies for treating AD have become the leading therapeutic way and emerging research globally with effective outcomes. The immune system is a complex player in the pathogenesis of Alzheimer's disease. Immunotherapy offers a promising avenue for treating this devastating condition by leveraging the body's natural defence mechanisms. Continued research is essential to unlock the full potential of this approach. Furthermore, we highlighted the impact of phase III clinical trials on intelligence and amyloid elimination in AD subjects treated with lecanemab and donanemab. We also talked about potential contributing variables and possible adverse reactions of anti-Aβ mAbs. In conclusion, we have collected data to explore novel immunotherapies breakthroughs based on tau, Aβ, and microglia and their mechanisms of action in AD from published articles and future perspectives.

Keywords

ADAmyloid-βTauActivePassive Immunotherapy

References

  1. Chaudhary RK, et al. Alzheimer’s disease: epidemiology, neuropathology, and neurochemistry. In: Computational and Experimental Studies in Alzheimer’s Disease. CRC Press; 2024. p. 1–14. [Google Scholar][Crossref]
  2. Thal DR, Murray ME, Dickson DW. Alzheimer’s disease (Aβ and Tau proteinopathy). In: Greenfield’s Neuropathology 10e Set. CRC Press; 2024. p. 1012– 1041. [Google Scholar][Crossref]
  3. Bermejo-Pareja F, Del Ser T. Controversial past, splendid present, unpredictable future: a brief review of Alzheimer disease history. Journal of Clinical Medicine. 2024;13(2):536. [Google Scholar][Crossref]
  4. Ortiz-Islas E, et al. Evolution of Alzheimer’s disease therapeutics: from conventional drugs to medicinal plants, immunotherapy, microbiotherapy and nanotherapy. Pharmaceutics. 2025;17(1):128. [Google Scholar][Crossref]
  5. Yu Y, et al. Amyloid‐β in Alzheimer’s disease: structure, toxicity, distribution, treatment, and prospects. iBrain. 2024;10(3):266–289. [Google Scholar][Crossref]
  6. Abubakar M. Exploring the pivotal association of AI in cancer stem cells detection and treatment. Proceedings of Anticancer Research. 2024;8(5):52–63. [Google Scholar][Crossref]
  7. Yang X, et al. Contribution of zinc accumulation to ischemic brain injury and its mechanisms about oxidative stress, inflammation, and autophagy: an update. Metallomics. 2024;16(3):mfae012. [Google Scholar][Crossref]
  8. Abubakar M. Overview of skin cancer and risk factors. International Journal of General Practice Nursing. 2024;2(3):42–56. [Google Scholar][Crossref]
  9. Huang Y, et al. Innate and adaptive immunity in neurodegenerative disease. Cellular and Molecular Life Sciences. 2025;82(1):68. [Google Scholar][Crossref]
  10. Vergini D-E, Hadjipavlou-Litina D. A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018–present). Expert Opinion on Therapeutic Patents. 2025;35(3):291–304. [Google Scholar][Crossref]
  11. Kang S-J, et al. Immune cell-enriched single-cell RNA sequencing unveils the interplay between infiltrated CD8+ T resident memory cells and choroid plexus epithelial cells in Alzheimer’s disease. Journal of Neuroimmunology. 2025;398:578488. [Google Scholar][Crossref]
  12. Khan RMA, Abubakar M, Rehman B. Novel immunotherapy strategies for brain tumors. Clinical Neuroscience Research. 2024;2(4):26–42. [Google Scholar][Crossref]
  13. Akyuz E, et al. An expanded narrative review of International Journal of Medical and All Body Health Research www.allmedicaljournal.com neurotransmitters on Alzheimer’s disease: the role of therapeutic interventions on neurotransmission. Molecular Neurobiology. 2025;62(2):1631–1674. [Google Scholar][Crossref]
  14. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. The Tohoku Journal of Experimental Medicine. 2010;220(2):95–106. [Google Scholar][Crossref]
  15. Ma H, Tao W, Zhu S. T lymphocytes in the intestinal mucosa: defense and tolerance. Cellular & Molecular Immunology. 2019;16(3):216–224. [Google Scholar][Crossref]
  16. Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS & Neurological Disorders – Drug Targets (Formerly Current Drug Targets – CNS & Neurological Disorders). 2009;8(1):7–15. [Google Scholar][Crossref]
  17. Gilman S, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553–1562. [Google Scholar][Crossref]
  18. Shah S, Federoff HJ. Therapeutic potential of vaccines for Alzheimer’s disease. Immunotherapy. 2011;3(2):287–298. [Google Scholar][Crossref]
  19. Vogt A-CS, et al. Alzheimer’s disease: a brief history of immunotherapies targeting amyloid β. International Journal of Molecular Sciences. 2023;24(4):3895. [Google Scholar][Crossref]
  20. Cai H, et al. Amyloid-β-targeted therapies for Alzheimer’s disease: currently and in the future. Ageing and Neurodegenerative Diseases. 2023;3(3):N/A–N/A. [Google Scholar][Crossref]
  21. CV, Zacharias M. From monomer to fibril: Aβ‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. Proteins: Structure, Function, and Bioinformatics. 2020;88(12):1592–1606. [Google Scholar][Crossref]
  22. Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opinion on Investigational Drugs. 2023;32(2):89–94. [Google Scholar][Crossref]
  23. Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s Research & Therapy. 2021;13:1–14. [Google Scholar][Crossref]
  24. Azargoonjahromi A. Immunotherapy in Alzheimer’s disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline. Journal of Pharmacy and Pharmacology. 2024;76(9):1115–1131. [Google Scholar][Crossref]
  25. Rudrabhatla P, Jaffe H, Pant HC. Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer’s NFTs. The FASEB Journal. 2011;25(11):3896. [Google Scholar][Crossref]
  26. Song C, et al. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Translational Neurodegeneration. 2022;11(1):18. [Google Scholar][Crossref]
  27. Iqbal K, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2005;1739(2–3):198–210. [Google Scholar][Crossref]
  28. Durairajan SSK, et al. Unraveling the interplay of kinesin-1, tau, and microtubules in neurodegeneration associated with Alzheimer’s disease. Frontiers in Cellular Neuroscience. 2024;18:1432002. [Google Scholar][Crossref]
  29. Javadpour P, et al. To be or not to be: PP2A as a dual player in CNS functions, its role in neurodegeneration, and its interaction with brain insulin signaling. Cellular and Molecular Life Sciences. 2019;76(12):2277–2297. [Google Scholar][Crossref]
  30. Yang L, et al. Stress level of glucocorticoid exacerbates neuronal damage and Aβ production through activating NLRP1 inflammasome in primary cultured hippocampal neurons of APP -PS1 mice. International Immunopharmacology. 2022;110:108972. [Google Scholar][Crossref]
  31. Rafiyan M, et al. Experimental animal models of chronic inflammation. Current Research in Immunology. 2023;4:100063. [Google Scholar][Crossref]
  32. Macedo AC, et al. The use of tau PET to stage Alzheimer disease according to the Braak staging framework. Journal of Nuclear Medicine. 2023;64(8):1171–1178. [Google Scholar][Crossref]
  33. Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nature Reviews Neuroscience. 2016;17(4):201–207. [Google Scholar][Crossref]
  34. Farzan M, et al. The emerging role of the microglia triggering receptor expressed on myeloid cells (TREM2) in multiple sclerosis. Experimental Neurology. 2024;115071. [Google Scholar][Crossref]
  35. Rutsch A, Kantsjö JB, Ronchi F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Frontiers in Immunology. 2020;11:604179. [Google Scholar][Crossref]
  36. Vroom MM, Dodart J-C. Active immunotherapy for the prevention of Alzheimer’s and Parkinson’s disease. Vaccines. 2024;12(9):973. [Google Scholar][Crossref]
  37. Rahman MM, et al. Exploring the management approaches of cytokines including viral infection and neuroinflammation for neurological disorders. Cytokine. 2022;157:155962. [Google Scholar][Crossref]
  38. Wolff AS, et al. B cells and autoantibodies in AIRE deficiency. Biomedicines. 2021;9(9):1274. [Google Scholar][Crossref]
  39. Zhao Z, et al. Current anti-amyloid-β therapy for Alzheimer’s disease treatment: from clinical research to nanomedicine. International Journal of Nanomedicine. 2023;18:7825–7845. [Google Scholar][Crossref]
  40. Paul P, et al. The evolution of Alzheimer’s disease therapies: a comprehensive review. Annals of Medical Science & Research. 2024;3(1):11–19. [Google Scholar][Crossref]
  41. Cummings J, et al. Drug development in Alzheimer’s disease: the path to 2025. Alzheimer’s Research & Therapy. 2016;8:1–12. [Google Scholar][Crossref]
  42. Panza F, et al. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy. 2012;4(2):213–238. [Google Scholar][Crossref]
  43. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nature Reviews Neurology. 2018;14(7):399–415. [Google Scholar][Crossref]
  44. Jucker M, Walker LC. Alzheimer’s disease: from immunotherapy to immunoprevention. Cell. 2023;186(20):4260–4270. [Google Scholar][Crossref]
  45. Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease. Current Neuroph armacology. 2020;18(11):1106–1125. [Google Scholar][Crossref]
  46. Heidebrink JL, Paulson HL. Lessons learned from approval of aducanumab for Alzheimer’s disease. Annual Review of Medicine. 2024;75(1):99–111. [Google Scholar][Crossref]

How to Cite

Khan, M. A., Ashfaq, Q. U. A., Abbas, D., Atiq, B., Saif, F., & Munir, M. J. (2025). Exploring Immunotherapeutic Approaches for Alzheimer’s Disease. International Journal of Medical and All Body Health Research, 6(2), 21-27. https://doi.org/10.54660/IJMBHR.2025.6.2.21-27

Khan, Mubashir Ahmad, et al. "Exploring Immunotherapeutic Approaches for Alzheimer’s Disease." International Journal of Medical and All Body Health Research, vol. 6, no. 2, 2025, pp. 21-27. https://doi.org/10.54660/IJMBHR.2025.6.2.21-27.

Khan, M. A., Ashfaq, Q. U. A., Abbas, D., Atiq, B., Saif, F. and Munir, M. J. (2025) 'Exploring Immunotherapeutic Approaches for Alzheimer’s Disease', International Journal of Medical and All Body Health Research, 6(2), pp. 21-27. doi: 10.54660/IJMBHR.2025.6.2.21-27.

Khan MA, Ashfaq QUA, Abbas D, Atiq B, Saif F, Munir MJ. Exploring Immunotherapeutic Approaches for Alzheimer’s Disease. International Journal of Medical and All Body Health Research. 2025;6(2):21-27. doi:10.54660/IJMBHR.2025.6.2.21-27

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASE

A newly published article may take a few days to appear on these services.